Abilify approved for severe treatment of bipolar We disorder in adolescents Otsuka Pharmaceutical Co., Ltd. And Bristol-Myers Squibb Organization provides announced that the U.S. Food and Medication Administration accepted the supplemental New Drug Program for ABILIFY for the acute treatment of manic and combined episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric individuals . ABILIFY has been accepted for the severe and maintenance treatment of manic and combined episodes connected with Bipolar I Disorder with or without psychotic features in adults since September 2004 and March 2005, respectively.D., Medical Director, Prevention and Recognition Program, The Zucker Hillside Assistant and Medical center Professor of Psychiatry and Behavioral Sciences, Albert Einstein University of Medicine, Glen Oaks, New York.D., Chief Executive Officer, Chief and President Operating Officer, Otsuka Pharmaceutical Advancement and Commercialization, Inc.D., Ph.D., Executive Vice President, Chief Scientific President and Officer, Development and Research, Bristol-Myers Squibb.Features of the scholarly research human population are shown in Desk 1Table 1Baseline Features of the 34,989 Study Newborns. All of the infants were from well-baby nurseries. The median age at the right time of collection of follow-up samples was 3.6 weeks . Overall, 177 newborns tested positive for CMV on screening by way of rapid tradition, PCR assay, or both. No study-related adverse occasions were observed. Newborn CMV Screening with Saliva Fast Culture and Real-Time PCR Assay Rapid Tradition and Liquid-Saliva PCR Assay During stage 1, liquid-saliva specimens were collected from 17,662 newborns and tested for CMV with the use of rapid liquid-saliva and tradition real-time PCR assay.